Navigation Links
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
Date:5/2/2013

CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 12/952,238 (the '238 application).  The application includes composition of matter claims on a new class of melanocortin receptor- specific peptides for sexual dysfunction and other indications.

The '238 application is the first patent application to issue covering a novel family of melanocortin-4 receptor agonist peptides.  The melanocortin-4 receptor mediates sexual response, and agonists have been studied for treatment of both erectile dysfunction and female sexual dysfunction.  Palatin's bremelanotide product, a melanocortin-4 receptor agonist peptide drug administered using an autoinjector, has recently completed Phase 2 human studies for female sexual dysfunction, with pivotal Phase 3 clinical studies scheduled to start later this year.

The peptides in the '238 application demonstrated effects on sexual function in animal models.  Palatin is evaluating these peptides as potential follow-on or second generation products for treatment of sexual dysfunction.  The melanocortin-4 receptor also has potential utility in treatment of obesity, metabolic syndrome and other indications.

"As we move into Phase 3 with bremelanotide for female sexual dysfunction, we are pleased to have new peptides with improved profiles suitable for use as second generation products," stated Carl Spana , Ph.D., President and CEO of Palatin.

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies To Present At The 25th Annual ROTH Conference
2. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
3. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
4. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
5. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
6. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
8. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) has announced the addition ... Testing services - Global Forecast to 2020" report ... market is estimated to be worth around $2.5 billion ... during the forecast period of 2014 to 2020 ... protein consumption, increasing adoption of advanced genetic technologies for ...
(Date:5/28/2015)... -- Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... institutional healthcare investors to purchase an aggregate of approximately ... at-the-market registered direct offering and a concurrent private placement ... Company entered into a definitive purchase agreement with these ... an aggregate of 3,000,000 shares of its common stock ...
(Date:5/28/2015)... May 28, 2015  PDS Biotechnology Corp. announces ... treatment targeting HPV-16, has generated strong T-cell responses ... pre-cervical cancer is treated by surgical removal of ... effective non-surgical alternative. Results show that it primes ... recognize, target, and kill precancerous and cancerous cells ...
(Date:5/28/2015)... New York and London (PRWEB) May 28, 2015 ... CFD-focused provider of Computer Aided Engineering software, announced ... Solid Research, Inc. (PSRI). CD-adapco will provide state-of-the-art ... PSRI members will share their expertise and experiences ... chemical and refining industry members and advance the ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Auxogyn, Inc., a privately held medical technology company ... acquired an exclusive license from Stanford University to develop ... in the field of assisted reproduction to significantly improve ... procedures. The technology licensed from Stanford is ...
... Calif., Oct. 4 Dainippon Sumitomo Pharma Co., Ltd. ... have entered into an option agreement to co-develop a ... the agreement, DSP has received an option for exclusive ... a promising cell therapy drug candidate being developed by ...
... BOTHELL, WA and VANCOUVER, Oct. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... of OncoGenex will present at the 9th Annual BIO Investor ... The Palace Hotel in San Francisco, CA. Live ... Relations page of the OncoGenex Web site at http://ir.oncogenex.com ...
Cached Biology Technology:Auxogyn Licenses Non-invasive Embryo Assessment Technology From Stanford University 2Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery 2OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2
(Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... a well-rounded UAS delegation representing private industry, government, and academia, ... AUVSI,s Unmanned 2015 conference last week in Atlanta ... UAS industry met with over 200 hundred people from companies ... ecosystem. "Our message is clear and consistent," ... Rich Knoll . "If you want to fly UAS, you ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... de dezembro de  2012 A Integrated Biometrics, ... a certificação pelo FBI de sua novíssima tecnologia ... IB criou o novo produto usando a tecnologia ... com um transistor de película fina (TFT). A ...
... methodologies of identifying genes that contribute to the ... in several immune-system-related pathways contribute to development of ... 4 in the open-access journal PLOS ONE ... function in autism by integrating analysis of autism-associated ...
... and Cargill have renewed their partnership to eliminate lymphatic filariasis ... disease that affects over 2 million Haitians and is the ... is truly a national disease in Haiti and 87 percent ... of coastal Haiti, as much as half of the population ...
Cached Biology News:Integrated Biometrics Apresenta Sherlock, o Menor, Mais Leve e Fino Sensor Appendix F Mobile ID 2Combining two genome analysis approaches supports immune system contribution to autism 2Combining two genome analysis approaches supports immune system contribution to autism 3Cargill expands support of Notre Dame Haiti Program 2Cargill expands support of Notre Dame Haiti Program 3
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Agarose Gel Loading Dye Mixture 6X...
Biology Products: